Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Breast Cancer

30 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCBRE1696

    06/15/2017

    Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer

    Basic Science

    VICCBRE03103

    01/22/2004

    Breast Tissue/Body Fluids Repository (SPORE)

    Basic Science

    VCCBRE0057

    10/27/2000

    Nashville Breast Health Study

    Diagnostic

    ECOGBREEAI142

    08/09/2017

    (18F) Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer

    Diagnostic

    VICCBRE0588

    03/07/2006

    MRI Evaluation Of Breast Tumor Growth And Treatment Response (SPORE)

    Other

    ECOGBREE2Z04-M

    06/11/2008

    Quality of LIfe in Younger Breast Cancer Survivors

    Other

    CTSUBREC70301-M

    06/11/2007

    Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

    Other

    VICCBRE0704

    02/21/2007

    Developing In-Vivo Models of Human Breast Cancer

    Prevention

    VICCBRE1438

    06/19/2014

    A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measurement in the Prevention of Lymphedema following Locoregional Treatment for Breast Cancer

    Screening

    ECOGBREEA1141

    05/09/2017

    Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

    Treatment

    VICCBRE16126

    08/10/2017

    PHIb Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (MBC)

    Treatment

    VICCBRE15136

    07/27/2017

    A Phase II Trial of Atezolizumab (Anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer

    Treatment

    VICCBRE1727

    06/15/2017

    A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)

    Treatment

    ECOGBRES1418

    03/17/2017

    A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN+) After Neoadjuvant Chemotherapy

    Treatment

    VICCBRE15147

    01/20/2017

    A Randomized Phase II Trial of Fulvestrant with or without Ribociclib (LEE011) After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Advanced Hormone Receptor Positive, HER2 Negative Breast Cancer

    Treatment

    ECOGBREA011401

    12/16/2016

    Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    Treatment

    VICCBRE1642

    12/15/2016

    Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Treatment

    VICCBRE1640

    11/10/2016

    PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

    Treatment

    VICCBRE15120

    08/18/2016

    Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor-Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamic Markers (TBCRC035)

    Treatment

    NRGBREB-51

    04/13/2016

    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

    Treatment

    VICCBRE1557

    03/11/2016

    A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) with Paclitaxel in Patients with Triple Negative Metastatic Breast Cancer

    Treatment

    VICCBRE1546

    12/01/2015

    The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    ECOGBREEA1131

    09/24/2015

    A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

    Treatment

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Treatment

    CTSUNSABPBREB-47-M

    04/26/2012

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

    Treatment

    CTSUBRENB-43-M

    04/26/2012

    A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

    Treatment

    CTSUBRENCCTGMA32-M

    04/23/2012

    A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

    Treatment

    CTSUBRES1007-M

    05/25/2011

    Phase III randomized trial of standard adjuvant endocrine therapy +/- chemo in patients with 1-3 positive nodes, hormone receptor positive and Her2 negative breast cancer with recurrence score (RS) of 25 or less

    Treatment

    CTSUBREC40603-M

    12/07/2010

    Randomized Phase II 2 X 2 Factorial Trial Of The Addition Of Carboplatin +/- Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed By Dose-Dense AC In Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer


    Print this page for your doctor